Business Context and Reporting Period
Company: Prothena Corporation plc
Filing Type: Form 8-K (Current Report)
Date: December 11, 2013
Event: Entry into a Material Definitive Agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively, "Roche").
Key Financial Metrics and Deal Terms
This filing details a License, Development, and Commercialization Agreement rather than standard periodic financial results. Key financial terms include:
- Upfront and Near-Term Payments: $45.0 million total (upfront payment plus near-term clinical milestone).
- PRX002 Milestones: Up to $380.0 million for development, regulatory, and first commercial sale milestones.
- Ex-U.S. Commercial Milestones: Up to $175.0 million.
- Ex-U.S. Royalties: Tiered, high single-digit to high double-digit royalties in the teens on annual net sales.
- U.S. Profit Sharing: Costs and profits allocated 70% to Roche and 30% to Prothena for PRX002 in Parkinson's disease (unless Prothena opts out).
- U.S. Opt-Out Milestones: Up to $155.0 million in commercial sales milestones if Prothena opts out of co-development.
- U.S. Opt-Out Royalties: Tiered, single-digit to high double-digit royalties in the teens on annual net sales.
Note: The filing does not provide current revenue, profit, cash flow, debt, or liquidity figures for Prothena Corporation plc.
Material Changes and Strategic Shifts
The agreement represents a significant strategic partnership for Prothena's alpha-synuclein antibody portfolio, specifically PRX002 for Parkinson's disease.
- Licensing Rights: Prothena grants Roche an exclusive, worldwide license to develop, make, use, sell, and export the Licensed Products.
- Development Roles: Roche assumes primary responsibility for regulatory approval and commercialization after the filing of the investigational new drug application (IND) for PRX002. Roche will also handle clinical and commercial manufacture.
- Research Collaboration: Roche will fund a collaboration to optimize early-stage antibodies, potentially utilizing Roche's Brain Shuttle technology to enhance brain delivery.
Guidance, Risks, and Contingencies
Conditions Precedent: The agreement's effectiveness is contingent upon customary regulatory clearances, including the expiration of the Hart-Scott-Rodino (HSR) waiting period.
Termination Rights:
- Roche may terminate at will after the first anniversary (90 days' notice prior to first commercial sale; 180 days' notice after).
- Either party may terminate for material breach (uncured after 90 days) or insolvency.
- Termination may occur on a patent-by-patent basis if a party challenges a patent.
Risks: Forward-looking statements regarding the success of research, regulatory approval, efficacy, and milestone achievement involve significant uncertainties. Actual results may differ materially due to risks described in Prothena's Form 10-K and 10-Q filings.
Investor Verification Checklist
- Verify the status of the Hart-Scott-Rodino (HSR) regulatory clearance required for the agreement to become effective.
- Confirm the specific timeline for the filing of the investigational new drug application (IND) for PRX002, which triggers Roche's primary development responsibilities.
- Review Prothena's cash position to assess runway given the receipt of the $45.0 million upfront/near-term payment.
- Monitor the "Risk Factors" section of the most recent Form 10-K for details on clinical development risks and regulatory hurdles.
- Check for any future announcements regarding Prothena's decision to opt-in or opt-out of U.S. co-development and cost-sharing for PRX002.